| An Analysis of the Metabolic Syndrome and the Clinicopathologic Prognostic Factors Affecting Survival in Patients with Uterine Endometrial Cancer. |
|
Byung Hwa Jeon, Sang Wook Yi, Jung Won Park, Han Moie Park, Sang Soo Lee, Woo Seok Sohn |
|
Department of Obstetrics and Gynecology, Gangneung Asan Hospital, College of Medicine, University of Ulsan, Gangneung, Korea. bigmoie@gnah.co.kr |
|
|
| Abstract |
OBJECTIVE
We aimed to evaluate the metabolic syndrome and the clinicopathologic prognostic factors of endometrial cancer results from 35 surgically staged patients and to find out those novel prognostic factors. METHODS: This study is based on 35 endometrial cancer patients. Difference of survival rate in the following histologic parameters and parameter of metabolic syndrome was analyzed: age, body mass index (BMI), hypertension, insulin resistance, triglyceride, HDL-cholesterol, FIGO stage, tumor grade, myometrial invasion, cervical involvement, adnexal metastasis, and lympho-vascular space invasion (LVSI). Concerning lymph node involvement, the ratio of metastatic lymph node to dissected lymph node (metastatic ratio: MR) was calculated in total pelvic lymph node. MR was divided into less than 0.5 to more than 0.5. In each group, 5-year survival rate (5YSR) was analyzed and compared. RESULTS: The overall 5YSR for all 35 patients was 78.8%. The 5YSR for insulin resistance and normal insulin tolerance were 94.1%, 33.6% (p=0.009). LVSI, adnexal metastasis and MR of pelvic lymph node were independent prognostic factors for the endometrial cancer patients. CONCLUSION: Our results suggested that there was a relationship between insulin resistance and endometrial cancer and we confirmed the need for the treatment of metabolic disturbance and the prevention of metabolic syndrome aimed at correcting hormonal-metabolic disturbance in endometrial cancer patients. The MR of pelvic lymph node is thought that one of the most important prognostic factor of the endometrial cancer. |
| Key Words:
Endometrial cancer, Metabolic syndrome, Metastatic ratio, 5-year survival |
|
Full text via DOI
Download Citation
